1. Abraham, J. (1995), Science, Politics, and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation (New York: St. Martin’s Press).
2. Aggressive Research Intelligence Facility (2004a) Recombinant Human Alpha-Liduronidase for the Treatment of Patients with Mucopolysaccharidosis Type 1 (Birmingham).
3. Aggressive Research Intelligence Facility (2004b) Recombinant Human Alphagalactosidase for the Treatment of Patients with Fabry’s Disease (Birmingham).
4. Alster, N. (1991), ‘Henri Termeer’s Orphan Drug Strategy’, Forbes 147, pp. 202–7.
5. Asbury, C. H. (1985), Orphan Drugs: Medical Versus Market Value (Lexington MA: Lexington Books).